Osaic Holdings’s HCW Biologics HCWB Stock Holding History

Osaic Holdings’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20	Hold	4	–	–	﹤0.01%	7923
2026 Q1	$9	Hold	4	–	–	﹤0.01%	7746
2025 Q4	$25	Hold	4	–	–	﹤0.01%	7728
2025 Q3	$96	Hold	4	–	–	﹤0.01%	7748
2025 Q2	$103	Hold	4	–	–	﹤0.01%	7564
2025 Q1	$285	Buy	+4	New	+$352	﹤0.01%	7112

Other funds holding HCWB

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Osaic Holdings's HCWB Position: Q2 2026 in Review

Osaic Holdings held its HCW Biologics (HCWB) position steady in Q2 2026 at 4 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #7923.

Osaic Holdings first reported a position in HCWB in Q1 2025 and has held it in 6 quarters since. The position peaked at $285 in Q1 2025. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

Osaic Holdings held 4 shares of HCW Biologics worth $20 as of Q2 2026.
Osaic Holdings left its HCW Biologics share count unchanged in Q2 2026.
HCW Biologics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7923 holding.
Osaic Holdings first reported a position in HCW Biologics in Q1 2025 and has held it in 6 quarters since.
Osaic Holdings's HCW Biologics position peaked at $285 in Q1 2025.
12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.